NICE approves digital health therapies for psychosis treatment in the NHS
The National Institute for Health and Care Excellence (NICE) has officially approved three innovative digital therapies for incorporation into the treatment of psychosis within the NHS, pending further investigation into their benefits. This provisional approval, part of an early value assessment, encompasses AVATAR Therapy, SlowMo, and CareLoop, each targeting different aspects of psychosis...Read MoreMelatonin offers new hope for obesity prevention according to recent studies
Recent collaborative research spearheaded by the University of Granada (UGR) has unveiled significant findings regarding the use of melatonin in the prevention of obesity. This research, conducted by a team comprising experts from UGR’s Department of Pharmacology, the Federico Olóriz Neurosciences Institute, the Biosanitary Institute of Granada, and the University of Qatar, has shown...Read Moreby Nicholas FeenieApril 23, 2024 Artificial Intelligence, Digital Health, Electronic Patient Records0 comments
AI enhances physician-patient communication, study reveals
UC San Diego Health, as one of the initial health institutions in the United States to integrate generative artificial intelligence (GenAI) into the Epic Systems electronic health record system, is at the forefront of digital health innovation. This integration facilitates the drafting of replies to patient inquiries, marking a significant step forward in medical communication. The...Read MoreTwenty years of research validates mediterranean diet’s role in lowering hypertension risk
A landmark study published in the European Journal of Clinical Nutrition has shed light on the enduring benefits of the Mediterranean diet in preventing hypertension (HTN) over an extensive 20-year period. Conducted among a group of initially non-hypertensive adults, this research marks a significant step in understanding long-term dietary impacts on health. Hypertension remains a critical...Read MoreEli Lilly’s Tirzepatide shows up to 66% reduction in sleep apnea severity in adults with obesity
In a recent development, Eli Lilly & Co. announced that its weight-loss medication, Tirzepatide, has shown promising results in alleviating symptoms of obstructive sleep apnea, a disorder primarily associated with obesity. This revelation emerged from two advanced clinical trials, wherein Tirzepatide significantly reduced the incidences of diminished or halted breathing during sleep by up...Read Moreby Nicholas FeenieApril 18, 2024 Artificial Intelligence, Big Data, Digital Health, Electronic Patient Records0 comments